You are here: Industry Insights > Cervical Cancer

News List

ASTRI's cervical cancer screening system receives recognition biospectrumasia
April 08, 2019
ASTRI's CCSMS is a convenient, effective and accurate scalable computer-aided diagnostic platform.
Vaccine, Screening Can Prevent Cervical Cancer Deaths drugs
January 16, 2019
About 4,000 women in the United States die from cervical cancer each year -- even though there's a preventive vaccine and screening to catch the disease early....
Cervical Cancer Screening Rates 'Unacceptably Low' drugs
January 09, 2019
Less than two-thirds of eligible 30- to 65-year-old women are up to date with cervical cancer screening, and Pap completion rates have decreased over time.....
HPV Ups Cervical Cancer Risk, Even With No Cellular Signs drugs
December 25, 2018
The presence of certain high-risk human papillomavirus (HPV) types predicts future risk for high-grade cervical cancer even among women with no cellular indications of cancer at baseline, according to a study published online Dec. 10 in Cancer....
New cervical cancer test 100% effective pharmatimes
December 21, 2018
A new cervical cancer test has been found to detect 100% of cervical cancers, according to a report published in The International Journal of Cancer.
UK cervical cancer screening rates fall to 21-year low pharmafile
November 29, 2018
A report by NHS Digital has revealed that cervical cancer screening coverage has fallen to 71.4%, down from 72% in 2017, marking the fourth year of decline in the figures and the lowest point in 21 years.
Guided Therapeutics Announces Extension of Distribution Agreement for Eastern Europe and Russia pharmafocusasia
November 12, 2018
Guided Therapeutics, Inc., the maker of a rapid and painless testing platform based on its patented biophotonic technology, today announced it has signed an extension of its distribution agreement with its Russian and Eastern European Sales and Marketing
FDA OKs MSD’s Keytruda for advanced cervical cancer pharmatimes
July 10, 2018
US regulators have given MSD’s Keytruda its first regulatory approval for a gynaecological cancer.
Global Cervical Cancer Diagnostics (Pap Testing, HPV Testing, Colposcopy and Cervical Biopsies) Mark biospace
March 22, 2018
The "Global Cervical Cancer Diagnostics Market: By Type By Age Group (<35 years, 35 years, >35 years) - 2018 Edition: Forecast to 2022" report has been added to Research And Markets' offering.
Speedy US review for MSD’s Keytruda in cervical cancer pharmatimes
March 15, 2018
US regulators will undertake a priority review of MSD’s Keytruda as a treatment for patients with advanced cervical cancer.

Previous page 1 2 3 4 Next page